Biomarker that will help predict if a person will develop fetal lung disease associated with TB infection and can be used to treat Mycobacterium tuberculosis infection.
Every individual who encounter Mycobacterium tuberculosis infection do not develop an active form of TB, such individuals may test positive for Mycobacterium tuberculosis infection or antibody test.
A protein interleukin-32 is found in such individuals which protect them from developing TB infection into an active form of TB or fetal lung disease. Interleukin-32 help immune cells of body to kill Mycobacterium tuberculosis bacteria in presence of Vitamin D. Vitamin D is very important for protecting individual from developing active form of TB, in presence of Vitamin D protein interleukin-32 induce killing of Mycobacterium tuberculosis.
Presences of biomarker interleukin-32 in patients with latent TB can be used to predict if such patients will develop active form of TB or never. Synthetic Interleukin-32 can be used to develop pharmaceutical substance to treat TB patients with deficiency of interleukin-32 as well.
Source : http://www.uclahealth.org/main.cfm?xyzpdqabc=0&id=561&action=detail&ref=2549
Last updated: 07-Sep -2014
B V Waghmare (2014). Interlukin 32 biomarker that will predict relapse of tuberculosis infection and will be used in treatment of TB http://www.medicalwebsite.org/2014/09/protein-that-protect-from-tb-infection.htmlEvery individual who encounter Mycobacterium tuberculosis infection do not develop an active form of TB, such individuals may test positive for Mycobacterium tuberculosis infection or antibody test.
A protein interleukin-32 is found in such individuals which protect them from developing TB infection into an active form of TB or fetal lung disease. Interleukin-32 help immune cells of body to kill Mycobacterium tuberculosis bacteria in presence of Vitamin D. Vitamin D is very important for protecting individual from developing active form of TB, in presence of Vitamin D protein interleukin-32 induce killing of Mycobacterium tuberculosis.
Presences of biomarker interleukin-32 in patients with latent TB can be used to predict if such patients will develop active form of TB or never. Synthetic Interleukin-32 can be used to develop pharmaceutical substance to treat TB patients with deficiency of interleukin-32 as well.
Source : http://www.uclahealth.org/main.cfm?xyzpdqabc=0&id=561&action=detail&ref=2549
Last updated: 07-Sep -2014
1 comment:
Post a Comment